BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 20, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

M-Vax: Phase II

Preliminary data from a 46-patient U.S. low-dose study of M-Vax showed that 65 percent of 23 treated patients had an immune response against autologous...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >